Evidence map›Paper›PMID 33216241›Full record

ArticleDigestive diseases and sciences2021

Value of Plasma Methylated SFRP2 in Prognosis of Gastric Cancer.

Haijiao Yan, Wenyu Chen, Kele Ge, Xizheng Mao, Xiaodong Li, Wensong Liu, Jun Wu

Abstract read
PubMed Publisher
In one paragraph

Article in Digestive diseases and sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. siRNA-based strategies to combat drug resistance in gastric cancer.Medical oncology (Northwood, London, England) · 2024
    Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Long-term persistence of gastric dysbiosis after eradication of Helicobacter pylori in patients who underwent endoscopic submucosal dissection for early gastric cancer.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2021
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Haijiao Yan *Oncology Department, Third Affiliated Hospital of Soochow University, Changzhou, 213003, People's Republic of China.
Wenyu Chen *Oncology Department, Third Affiliated Hospital of Soochow University, Changzhou, 213003, People's Republic of China.
Kele GeOncology Department, Third Affiliated Hospital of Soochow University, Changzhou, 213003, People's Republic of China.
Xizheng MaoOncology Department, Third Affiliated Hospital of Soochow University, Changzhou, 213003, People's Republic of China.
Xiaodong LiOncology Department, Third Affiliated Hospital of Soochow University, Changzhou, 213003, People's Republic of China.
Wensong LiuHepatobiliary Surgery Department, Third Affiliated Hospital of Soochow University, Changzhou, 213003, People's Republic of China.
Jun WuOncology Department, Third Affiliated Hospital of Soochow University, Changzhou, 213003, People's Republic of China. wujun1408@126.com.ORCID 0000-0002-6922-8762
Soochow University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSecreted frizzled-related protein 2 (SFRP2) in circulating tumor DNA (ctDNA) is related to gastric cancer (GC) proliferation. However, whether methylated SFRP2 in ctDNA serves as the biomarker in GC patients remains unknown.

aimsTo investigate the relationship between methylated SFRP2 and the clinical outcomes of GC patients.

methodsOne hundred and forty-eight GC patients receiving systemic chemotherapy were collected during 2015-2017. Aberrant SFRP2 methylation was detected before and after chemotherapy by digital PCR-based technologies.

resultsBaseline SFRP2 methylation positively correlated with lymph node status (P < 0.001), distant metastasis (P < 0.001) and TNM stage (P = 0.005). The top 50% methylated SFRP2 had shorter progression-free survival (PFS) and overall survival (OS) than those with bottom 50% in stage III GC patients (median PFS, 11.0 vs. NR months; HR 13.05; 95% CI 3.05-55.95; median OS 17.0 vs. NR months; HR 7.80; 95% CI 1.81-33.60) and stage IV GC patients (median PFS, 4.0 vs. 7.0 months; HR 2.74; 95% CI 1.58-4.78; median OS 12.0 vs. 16.0 months; HR 3.14; 95% CI 1.67-5.92). Besides, the increased methylated SFPR2 from baseline to post-treatment was related to the worse PFS and OS among stage IV patients (median PFS, 5.0 vs. 7.0 months; HR 2.17; 95% CI 1.25-3.76; median OS 12.0 vs. 15.5 months; HR 3.51; 95% CI 1.94-6.35), but not to stage III patients.

conclusionsSFRP2 methylation and dynamic change are associated with GC prognosis. Our findings provide potential biomarker detection approach in ctDNA for prognosis prediction and dynamic monitoring among GC patients.

Indexed as

AdultAgedAged, 80 and overBiomarkers, TumorFemaleGene Expression Regulation, NeoplasticHumansMaleMembrane ProteinsMiddle AgedSecreted Frizzled-Related ProteinsStomach NeoplasmsYoung AdultBiomarkers, TumorMembrane ProteinsSecreted Frizzled-Related ProteinsSFRP2 protein, humanCirculating tumor DNAGastric cancerMethylation SFRP2Prognosis

Identifiers

PMID33216241
OpenAlexW3102259779

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.